Factors associated with long-term progression or stability in primary open-angle glaucoma
- PMID: 11020404
- DOI: 10.1016/s0002-9394(00)00487-6
Factors associated with long-term progression or stability in primary open-angle glaucoma
Abstract
Purpose: To evaluate long-term risk factors for progression or stability in patients with primary open-angle glaucoma.
Method: We retrospectively included consecutively reviewed patients who had primary open-angle glaucoma for at least 5 years in this multicenter trial. Historical and clinical factors in these patients were evaluated for their association with stability or progression of the glaucoma.
Results: We included 218 patients in this study; of these, 34 progressed over an average length of follow-up of 45.5 +/- 30.0 months, and 184 were stable over an average of 72.8 +/- 18.3 months. The mean intraocular pressure over the follow-up period for the progressed group was 19.5 +/- 3.8 mm Hg and for the stable group 17. 2 +/- 3.1 mm Hg (P =.001). The average standard deviation of individual intraocular pressures was greater in the progressed group (5.1 mm Hg) than the stable group (3.9 mm Hg, P =.012). Baseline characteristics indicating a greater potential to progress were a larger cup-to-disk ratio (P <.001), a greater number of medications (P =.02), older age (P.007), and worse visual acuity (P =.003). However, no difference was observed in pressure levels that prevented progression in these subpopulations compared with the total sample size.
Conclusions: This study suggests that lowering the intraocular pressure is important in the treatment of primary open-angle glaucoma to help prevent long-term progression. Lowering the pressure, however, is not uniformly effective in preventing progression. Additionally, risk factors for progression do not further help identify pressure levels that prevent worsening of glaucoma.
Similar articles
-
Intraocular pressure fluctuation a risk factor for visual field progression at low intraocular pressures in the advanced glaucoma intervention study.Ophthalmology. 2008 Jul;115(7):1123-1129.e3. doi: 10.1016/j.ophtha.2007.10.031. Epub 2008 Feb 20. Ophthalmology. 2008. PMID: 18082889 Clinical Trial.
-
Effects of dorzolamide 2% added to timolol maleate 0.5% on intraocular pressure, retrobulbar blood flow, and the progression of visual field damage in patients with primary open-angle glaucoma: a single-center, 4-year, open-label study.Clin Ther. 2008 Jun;30(6):1120-34. doi: 10.1016/j.clinthera.2008.06.006. Clin Ther. 2008. PMID: 18640468 Clinical Trial.
-
Predictive factors for progressive optic nerve damage in various types of chronic open-angle glaucoma.Am J Ophthalmol. 2005 Jun;139(6):999-1009. doi: 10.1016/j.ajo.2004.12.056. Am J Ophthalmol. 2005. PMID: 15953429
-
Glaucoma in children: are we making progress?J AAPOS. 2006 Feb;10(1):7-21. doi: 10.1016/j.jaapos.2005.10.001. J AAPOS. 2006. PMID: 16527674 Review.
-
Low systemic vitamin D as a potential risk factor in primary open-angle glaucoma: a review of current evidence.Br J Ophthalmol. 2021 May;105(5):595-601. doi: 10.1136/bjophthalmol-2020-316331. Epub 2020 Jun 30. Br J Ophthalmol. 2021. PMID: 32606080 Review.
Cited by
-
Effects of chronic mild hyperoxia on retinal and choroidal blood flow and retinal function in the DBA/2J mouse model of glaucoma.PLoS One. 2022 Mar 25;17(3):e0266192. doi: 10.1371/journal.pone.0266192. eCollection 2022. PLoS One. 2022. PMID: 35333901 Free PMC article.
-
Simplifying "target" intraocular pressure for different stages of primary open-angle glaucoma and primary angle-closure glaucoma.Indian J Ophthalmol. 2018 Apr;66(4):495-505. doi: 10.4103/ijo.IJO_1130_17. Indian J Ophthalmol. 2018. PMID: 29582808 Free PMC article. Review.
-
Comparison between primary Ahmed valve implantation and primary trabeculectomy with mitomycin C in pseudophakic patients with exfoliative glaucoma.Graefes Arch Clin Exp Ophthalmol. 2023 Dec;261(12):3559-3567. doi: 10.1007/s00417-023-06233-8. Epub 2023 Oct 3. Graefes Arch Clin Exp Ophthalmol. 2023. PMID: 37787821
-
Efficacy and safety of newly developed preservative-free latanoprost 0.005% eye drops versus preserved latanoprost 0.005% in open angle glaucoma and ocular hypertension: 12-week results of a randomized, multicenter, controlled phase III trial.Int J Ophthalmol. 2021 Oct 18;14(10):1539-1547. doi: 10.18240/ijo.2021.10.10. eCollection 2021. Int J Ophthalmol. 2021. PMID: 34667730 Free PMC article.
-
The use of dorzolamide versus other hypotensive agents to prevent glaucomatous progression.Ther Clin Risk Manag. 2007 Oct;3(5):725-32. Ther Clin Risk Manag. 2007. PMID: 18472997 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources